Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Oct 25, 2021
- Accession no.
- 0001447362-21-000245
- Filed
- Oct 25, 2021
- Trade date
- Oct 21, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 9 non-derivative transactions. Open-market sales total $157.4K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 21, 2021 | Common Stock | SSaleDisposed | −600 | $62.50F2 | −$37,500 | 129,194 | Indirect | |
| Oct 21, 2021 | Common Stock | SSaleDisposed | −66 | $63.42F4 | −$4,185.72 | 129,128 | Indirect | |
| Oct 21, 2021 | Common Stock | SSaleDisposed | −167 | $64.40F5 | −$10,754.8 | 128,961 | Indirect | |
| Oct 21, 2021 | Common Stock | SSaleDisposed | −600 | $62.50F2 | −$37,500 | 152,034 | Indirect | |
| Oct 21, 2021 | Common Stock | SSaleDisposed | −67 | $63.42F4 | −$4,249.14 | 151,967 | Indirect | |
| Oct 21, 2021 | Common Stock | SSaleDisposed | −167 | $64.40F5 | −$10,754.8 | 151,800 | Indirect | |
| Oct 21, 2021 | Common Stock | SSaleDisposed | −600 | $62.50F2 | −$37,500 | 139,432 | Indirect | |
| Oct 21, 2021 | Common Stock | SSaleDisposed | −67 | $63.42F4 | −$4,249.14 | 139,365 | Indirect | |
| Oct 21, 2021 | Common Stock | SSaleDisposed | −166 | $64.40F5 | −$10,690.4 | 139,199 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $61.980 to $62.975, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 3 transactions in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $63.020 to $63.810, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 3 transactions in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $64.250 to $64.580, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 3 transactions in Table I.